Does Serum Tau Protein Predict the Outcome of Patients with Ischemic Stroke?
- 12 June 2010
- journal article
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 43 (3) , 241-245
Abstract
The prediction of outcome after ischemic stroke (IS) is currently based on indirect data from clinical and radiological evaluation. We evaluated the usefulness of serum Tau protein as possible prognostic markers for IS. Fifty-six patients with computed tomography-confirmed IS were enrolled. Blood samples were obtained on days 1, 3, 5, and 10 after stroke onset. Tau and S100BB serum levels were measured by commercially available enzyme-linked immunosorbent assay. Neurological deficits were quantified by the National Institute of Health Stroke Scale on days 1, 3, 5, and 10 of stroke. Functional disability was rated with the Barthel Index and Rankin Scale on days 1, 3, 5, and 10 and additionally 3 months after the stroke. Computed tomography scan was performed to calculate infarct volume on admission to hospital and on day 10 from the diagnosis of IS onset. Tau protein was detected in the serum of 47.8% patients with IS. Patients in whom Tau protein was detected in serum, when compared with patients without Tau protein, developed more severe neurological deficits, had worse functional status measured in the early and late phase of IS, and were found to have larger volume of infarction. However, Tau protein concentrations measured within the early phase of IS did not correlate with degrees of neurological deficit and disability in the early phase and also after 3 months of IS. Detection of Tau protein in the serum of patients with IS but not its concentration can be considered as a bad prognostic factor for the clinical outcome in early and late phase of IS.Keywords
This publication has 19 references indexed in Scilit:
- Applicability of Biomarkers in Ischemic StrokeCerebrovascular Diseases, 2007
- Enhanced Disruption of the Blood Brain Barrier by Intracarotid Mannitol Injection During Transient Cerebral Hypoperfusion in RabbitsJournal of Neurosurgical Anesthesiology, 2007
- Elevated Serum S100B Levels Indicate a Higher Risk of Hemorrhagic Transformation After Thrombolytic Therapy in Acute StrokeStroke, 2007
- Association of Serial Biochemical Markers With Acute Ischemic StrokeStroke, 2006
- Identification of Novel Brain BiomarkersClinical Chemistry, 2006
- Release of neurobiochemical markers of brain damage is related to the neurovascular status on admission and the site of arterial occlusion in acute ischemic strokeJournal of the Neurological Sciences, 2004
- Serum S100B Predicts a Malignant Course of Infarction in Patients With Acute Middle Cerebral Artery OcclusionStroke, 2004
- Novel Diagnostic Test for Acute StrokeStroke, 2004
- Serum S100βCancer, 2003
- S100B as a surrogate marker for successful clot lysis in hyperacute middle cerebral artery occlusionJournal of Neurology, Neurosurgery & Psychiatry, 2003